Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
All You Need to Know About Agenus (AGEN) Rating Upgrade to Strong Buy
01:01pm, Friday, 03'rd Apr 2026
Agenus (AGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Agenus (AGEN) is a Top Momentum Stock for the Long-Term
10:50am, Friday, 03'rd Apr 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year?
10:40am, Friday, 03'rd Apr 2026
Here is how Agenus (AGEN) and Ensign Group (ENSG) have performed compared to their sector so far this year.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACR2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that data from an investigator-initiated Phase II trial condu
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global ph
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
02:02am, Wednesday, 01'st Apr 2026
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Head-To-Head Analysis: Agenus (NASDAQ:AGEN) and VivoSim Labs (NASDAQ:VIVS)
01:31am, Friday, 27'th Mar 2026
VivoSim Labs (NASDAQ: VIVS - Get Free Report) and Agenus (NASDAQ: AGEN - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies b
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its March Stakeholder Webcast focused on continue
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACR26--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that preliminary results from an investigator-sponsored study evaluating b
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates
09:35pm, Monday, 16'th Mar 2026
Agenus (AGEN) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of a loss of $1.27 per share. This compares to a loss of $2.04 per share a year ago.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for th
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
07:30am, Tuesday, 10'th Mar 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment un
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
04:30pm, Wednesday, 04'th Mar 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Agenus--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-e
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACRIO26--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced new translational and clinical biomarker data from its Phase 1b C-800-01
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AACRIO--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilim
